Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM BSE: 507789 SECTOR: Pharmaceuticals & Drugs  20k   106   14

348.60
-1.35 (-0.39%)
NSE: Today, 03:40 PM

Price Summary

Today's High

₹ 357.9

Today's Low

₹ 345

52 Week High

₹ 418.9

52 Week Low

₹ 156

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

913.26 Cr.

Enterprise Value

887.11 Cr.

No. of Shares

2.62 Cr.

P/E

56.33

P/B

7.01

Face Value

₹ 5

Div. Yield

1.16 %

Book Value (TTM)

₹  49.73

CASH

26.15 Cr.

DEBT

0 Cr.

Promoter Holding

68.71 %

EPS (TTM)

₹  6.19

Sales Growth

20.3%

ROE

16.52 %

ROCE

22.64%

Profit Growth

14.82 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20.3%
3 Year10.66%
5 Year9.46%

Profit Growth

1 Year14.82%
3 Year39.49%
5 Year10.55%

ROE%

1 Year16.52%
3 Year13.37%
5 Year7.16%

ROCE %

1 Year22.64%
3 Year17.17%
5 Year10.16%

Debt/Equity

0

Price to Cash Flow

163.14

Interest Cover Ratio

96.8228691687127

CFO/PAT (5 Yr. Avg.)

1.86722778585223

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 68.71 0
Sep 2022 68.72 0
Jun 2022 68.71 0
Mar 2022 68.71 0
Dec 2021 70.34 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 39.4938711693632% for the Past 3 years.
  • The company has significantly decreased its debt by 6.7879 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 96.8228691687127.
  • The company has an efficient Cash Conversion Cycle of 5.3745765193629 days.
  • Company has a healthy liquidity position with current ratio of 3.24334801143018.
  • The company has a good cash flow management; CFO/PAT stands at 1.86722778585223.
  • The company has a high promoter holding of 68.71%.

 Limitations

  • The company has shown a poor revenue growth of 10.6650563204356% for the Past 3 years.
  • The company is trading at a high PE of 56.33.
  • The company is trading at a high EV/EBITDA of 30.0986.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
Net Sales 58.39 54.47 52.14 60.6 60.53
Total Expenditure 48.99 48.86 51.51 54.18 47.63
Operating Profit 9.4 5.61 0.63 6.42 12.9
Other Income 0.29 1.95 0.28 0.31 1.12
Interest 0.06 0.06 0.06 0.01 0.03
Depreciation 0.23 0.37 0.65 0.19 0.2
Exceptional Items 0 0 0 -5.8 0
Profit Before Tax 9.4 7.14 0.2 0.72 13.79
Tax 2.83 1.73 0.18 0.35 3.38
Profit After Tax 6.56 5.41 0.02 0.37 10.41
Adjusted EPS (Rs) 2.51 2.06 0.01 0.14 3.97

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 126.53 166.83 158.57 187.95 226.1
Total Expenditure 137.64 157.49 150.04 168.87 200.3
Operating Profit -11.11 9.34 8.53 19.08 25.79
Other Income 0.46 1.43 2.53 4.39 3.34
Interest 0.66 0.75 0.51 0.51 0.29
Depreciation 0.32 1.02 1.13 1.09 1.53
Exceptional Items 0 0 0 0 0
Profit Before Tax -11.63 9 9.41 21.87 27.32
Tax -0.08 1.79 1.54 4.81 7.73
Net Profit -11.55 7.22 7.87 17.06 19.59
Adjusted EPS (Rs.) -4.41 2.75 3 6.51 7.48

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.1
Total Reserves 84.95 91.37 97.93 108.83 117.76
Borrowings 0 0 0 0 0
Other N/C liabilities 3.19 3.12 3.09 1.88 3.44
Current liabilities 28.58 28.19 34.57 40.4 34.16
Total Liabilities 129.81 135.78 148.69 164.2 168.45
Assets
Net Block 21.32 21.64 24.44 25.72 24.75
Capital WIP 0.98 1.89 1.9 0 0
Intangible WIP 2.06 2.06 0 0 0
Investments 0 0 11.39 12.06 20.58
Loans & Advances 10.84 12.63 14.53 5.66 9.93
Other N/C Assets 0 0 0.13 0.29 2.42
Current Assets 94.61 97.56 96.31 120.48 110.78
Total Assets 129.81 135.78 148.69 164.2 168.45
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations -11.63 9 9.41 21.87 27.32
Adjustment 1.26 0.33 -0.57 -2.09 2.91
Changes in Assets & Liabilities 8.79 19.71 4.84 11.59 -17.13
Tax Paid 0 1.85 -1.8 -3.15 -7.5
Operating Cash Flow -1.58 30.9 11.89 28.22 5.6
Investing Cash Flow -3.37 -0.83 -11.07 -2.26 -26.21
Financing Cash Flow -0.6 -6.05 -1.82 -6.83 -12.3
Net Cash Flow -5.55 24.02 -1.01 19.13 -32.91

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 70.34 68.71 68.71 68.72 68.71
aresko progressive... 65.71 64.09 20.36 20.36 20.36
infinity holdings - - 25.24 25.24 25.24
infinity holdings ... - - 18.15 18.15 18.15
rajpal singh kochh... 4.63 4.63 4.63 4.63 4.63
infinity consumer ... - - 0.33 0.33 0.33
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 29.66 31.29 31.29 31.28 31.29
vanaja sundar iyer - - 1.78 2.15 2.15
mukul mahavir agra... - - 1.77 1.77 1.77
manish gupta - 1.62 1.62 1.62 1.62
iepf - 1.56 - - -
investor education... - - - - -
investor education... - - - - -
iepf authority 1.56 - - - -
investor education... - - - 1.56 1.56
investor education... - - 1.56 - -
sanjiv kumar dudeja - - - - 1.41
sanjiv kumar dud... 1.41 1.41 1.41 1.41 -
si investments and... - 1.41 - - -
lincoln p coelho 1.16 1.18 1.18 1.18 1.18
rajasthan global s... - 1.12 - - -
foreign institutio... - - - 0.13 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ3FY22 23 Feb 2022

Company News

Jagsonpal Pharma - Quaterly Results9 Nov 2022, 7:09PM Jagsonpal Pharma - Quaterly Results9 Nov 2022, 7:09PM Jagsonpal Pharmaceuticals informs about allotment of ESOP 19 Sep 2022, 9:51AM Jagsonpal Pharma - Quaterly Results9 Aug 2022, 7:35PM Jagsonpal Pharma - Quaterly Results9 Aug 2022, 7:35PM Jagsonpal Pharmaceuticals informs about certificate20 Jul 2022, 9:54AM Jagsonpal Pharmaceuticals informs about change in KMPs16 Jul 2022, 3:11PM Jagsonpal Pharmaceuticals informs about letter of offer31 May 2022, 4:34PM Jagsonpal Pharma - Quaterly Results30 May 2022, 6:30PM Jagsonpal Pharma - Quaterly Results30 May 2022, 6:30PM Jagsonpal Pharmaceuticals informs about board meeting4 May 2022, 9:56AM Jagsonpal Pharmaceuticals informs about clarification28 Feb 2022, 4:53PM Jagsonpal Pharmaceuticals informs about investor presentation22 Feb 2022, 10:07AM Jagsonpal Pharmaceuticals enters into agreement with Suvinys Developers18 Feb 2022, 11:37AM Jagsonpal Pharmaceuticals informs about supply agreement 18 Feb 2022, 11:32AM Jagsonpal Pharma - Quaterly Results11 Feb 2022, 1:37PM Jagsonpal Pharma - Quaterly Results11 Feb 2022, 1:37PM Jagsonpal Pharmaceuticals informs about compliance certificate13 Jan 2022, 1:46PM Jagsonpal Pharmaceuticals informs about record date for purpose of interim dividend20 Oct 2021, 1:08PM Jagsonpal Pharma - Quaterly Results19 Oct 2021, 5:25PM Jagsonpal Pharma - Quaterly Results19 Oct 2021, 5:25PM Jagsonpal Pharmaceuticals informs about board meeting12 Oct 2021, 10:04AM Jagsonpal Pharmaceuticals informs about newspaper advertisements7 Sep 2021, 3:43PM Jagsonpal Pharmaceuticals informs about press release16 Aug 2021, 10:09AM Jagsonpal Pharmaceuticals informs about disclosure29 Jul 2021, 1:27PM Jagsonpal Pharmaceuticals informs about clarification12 Jul 2021, 3:35PM Jagsonpal Pharmaceuticals informs about certificate28 Oct 2020, 3:27PM Jagsonpal Pharmaceuticals informs about annual secretarial compliance report 1 Jul 2020, 3:35PM

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jagsonpal Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 5.5981 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jagsonpal Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jagsonpal Pharma , the EPS growth was 14.823460752845 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jagsonpal Pharma has OPM of 11.4085698729791 % which is a bad sign for profitability.
     
  • ROE: Jagsonpal Pharma have a average ROE of 16.5217035565904 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Jagsonpal Pharma

X